

**Title:**

**Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients**

**Corresponding author:** Dr. Anu Jacob  
Department of Neurology  
The Walton Centre NHS Foundation Trust  
Liverpool, UK.  
Email: [anu.jacob@thewaltoncentre.nhs.uk](mailto:anu.jacob@thewaltoncentre.nhs.uk)  
Telephone: +44 151 529 5770

**Authors:**

Daniel H Whittam BMBS MRCP<sup>1,2</sup>, Alvaro Cobo-Calvo MD PhD<sup>3</sup>, A Sebastian Lopez-Chiriboga MD<sup>4</sup>, Santiago Pardo BA<sup>5</sup>, Matthew Gornall BSc<sup>6</sup>, Silvia Cicconi MSc<sup>6</sup>, Alexander Brandt MD<sup>7</sup>, Klaus Berek MD<sup>8</sup>, Thomas Berger MD MSc<sup>9</sup>, Ilijas Jelcic MD<sup>10</sup>, Grace Gombolay MD<sup>5,11</sup>, Luana Micheli Oliveira MD<sup>12</sup>, Dagoberto Callegaro MD PhD<sup>12</sup>, Kimihiko Kaneko MD PhD<sup>13</sup>, Tatsuro Misu MD PhD<sup>13</sup>, Marco Capobianco MD<sup>14</sup>, Emily Gibbons MBChB MRCP<sup>1,2</sup>, Venkatraman Karthikeyan MBBS MD DM<sup>1</sup>, Bruno Brochet MD PhD<sup>15</sup>, Bertrand Audoin MD PhD<sup>16</sup>, Guillaume Mathey MD<sup>17</sup>, David Laplaud MD PhD<sup>18</sup>, Eric Thouvenot MD PhD<sup>19</sup>, Mikael Cohen MD<sup>20</sup>, Ayman Tourbah MD PhD<sup>21</sup>, Elisabeth Maillart MD<sup>22</sup>, Jonathan Ciron MD<sup>23</sup>, Romain Deschamps MD<sup>24</sup>, Damien Biotti MD<sup>25</sup>, Kevin Rostasy MD<sup>26</sup>, Rinze Neuteboom MD PhD<sup>27,28</sup>, Cheryl Hemingway PhD<sup>29</sup>, Rob Forsyth FRCPCH PhD<sup>30</sup>, Marcelo Matiello MD<sup>5</sup>, Stewart Webb MBChB FRCP<sup>31</sup>, David Hunt MBChB MRCP PhD<sup>32</sup>, Katy Murray MBChB MRCP PhD<sup>32</sup>, Yael Hacohen MRCPC DPhil<sup>29,33</sup>, Ming Lim PhD<sup>34,35</sup>, M Isabel Leite DPhil<sup>36</sup>, Jacqueline Palace DM FRCP<sup>36</sup>, Tom

Solomon PhD FRCP<sup>1,2</sup>, Andreas Lutterotti MD<sup>10</sup>, Kazuo Fujihara MD PhD<sup>13</sup>, Ichiro Nakashima MD PhD<sup>37</sup>, Jeffrey L. Bennett MD PhD<sup>38</sup>, Lekha Pandit MD DM PhD<sup>39</sup>, Tanuja Chitnis MD<sup>5</sup>, Brian G. Weinshenker MD FRCP<sup>4</sup>, Brigitte Wildemann MD<sup>40</sup>, Douglas Kazutoshi Sato MD PhD<sup>12,13,41</sup>, Su-Hyun Kim MD PhD<sup>42</sup>, Saif Huda MD PhD<sup>1,2</sup>, Ho Jin Kim MD PhD<sup>42</sup>, Markus Reindl PhD<sup>8</sup>, Michael Levy MD PhD<sup>5</sup>, Sven Jarius MD<sup>40</sup>, Silvia Tenenbaum MD<sup>43</sup>, Friedemann Paul MD<sup>7</sup>, Sean Pittock MD<sup>4</sup>, Romain Marignier MD PhD<sup>3</sup>, Anu Jacob MD DM FRCP<sup>1,2,44</sup>.

# **Author affiliations:**

<sup>1</sup> Department of Neurology, The Walton Centre NHS Foundation Trust, Liverpool, UK.

<sup>2</sup> Institute of Infection and Global Health, University of Liverpool, Liverpool, UK.

<sup>3</sup> Pathologies de la Myéline et Neuro-inflammation, Hôpital Neurologique Pierre Wertheimer Hospices Civils de Lyon, Lyon, France; Centre de Référence des Maladies Inflammatoires Rares du Cerveau et de la Moelle and INSERM U1028, CNRS UMR 5292, Lyon 1 University, Center for Research in Neuroscience of Lyon, Lyon, France.

<sup>4</sup> Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.

<sup>5</sup> Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.

<sup>6</sup> Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, UK.

<sup>7</sup> Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité Universitätsmedizin Berlin, Berlin, Germany.

<sup>8</sup> Medical University of Innsbruck, Innsbruck, Austria.

<sup>9</sup> Department of Neurology, Medical University of Vienna, Vienna, Austria.

<sup>10</sup> UniversitätsSpital Zürich, Zürich, Switzerland.

<sup>11</sup> Emory & Children's Pediatric Institute, Atlanta, Georgia, USA.

- <sup>12</sup> Hospital das Clinicas, Faculty of Medicine, University of São Paulo, São Paulo, Brazil.
- <sup>13</sup> Tohoku University Graduate School of Medicine, Sendai, Japan.
- <sup>14</sup> Neurology Dept. - Regional MS Centre, S. Luigi University Hospital, Orbassano, Italy.
- <sup>15</sup> CHU de Bordeaux & INSERM U 1215, University of Bordeaux, Bordeaux, France.
- <sup>16</sup> Aix Marseille University, APHM, Hôpital de La Timone, Marseille, France.
- <sup>17</sup> Nancy University Hospital and Inserm CIC 1433, Nancy, France.
- <sup>18</sup> Nantes University Hospital, Nantes, France.
- <sup>19</sup> Hôpital Carémeau, Nimes University Hospital, Nimes, France.
- <sup>20</sup> Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Nice, France.
- <sup>21</sup> Reims University Hospital, University of Reims Champagne-Ardenne, Reims, and LPN  
EA 2027, University of Paris VIII, Saint-Denis, France.
- <sup>22</sup> Pitié-Salpêtrière Hospital, APHP, Paris, France.
- <sup>23</sup> Poitiers University Hospital, Poitiers, France.
- <sup>24</sup> Fondation A. De Rothschild, Paris, France.
- <sup>25</sup> University Hospital of Purpan, Toulouse, France.
- <sup>26</sup> Department of Pediatric Neurology, Children's Hospital Datteln, University  
Witten/Herdecke, Witten, Germany
- <sup>27</sup> Department of Paediatric Neurology, Erasmus MC-Sophia, Rotterdam, The Netherlands
- <sup>28</sup> Department of Neurology, MS Centre ErasMS, Erasmus MC, Rotterdam, The Netherlands
- <sup>29</sup> Department of Paediatric Neurology, Great Ormond Street Hospital for Children, London,  
UK
- <sup>30</sup> Institute of Neuroscience, Newcastle University, Newcastle, UK.
- <sup>31</sup> Department of Neurology, Queen Elizabeth University Hospital, Glasgow, UK.
- <sup>32</sup> Anne Rowling Regenerative Neurology Clinic, University of Edinburgh, Edinburgh, UK.

<sup>33</sup> Department of Neuroinflammation, Queen Square MS Centre, UCL Institute of Neurology, London, UK.

<sup>34</sup> Children's Neuroscience, Evelina London Children's Hospital @ Guy's and St Thomas' NHS Foundation Trust, London, UK.

<sup>35</sup> Faculty of Life Sciences and Medicine, King's College London, London, UK.

<sup>36</sup> Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, UK.

<sup>37</sup> Department of Neurology, Tohoku Medical and Pharmaceutical University, Sendai, Japan.

<sup>38</sup> Departments of Neurology and Ophthalmology, Program in Neuroscience, University of Colorado School of Medicine, Aurora, Colorado, USA.

<sup>39</sup> Nitte University, Mangaluru, Karnataka, India.

<sup>40</sup> Molecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany.

<sup>41</sup> Pontificia Universidade Catolica Rio Grande Do Sul, Porto Alegre RS, Brazil.

<sup>42</sup> Research Institute and Hospital of National Cancer Center, Goyang, Republic of Korea.

<sup>43</sup> National Pediatric Hospital Dr. Juan P. Garrahan, Ciudad Autónoma de Buenos Aires, Argentina.

<sup>44</sup> The Cleveland Clinic Abu Dhabi, United Arab Emirates.

**Title character count: 95**

**Abstract word count: 195**

**Manuscript word count: 3350**

**Number of references: 37**

**Number of tables: 2**

**Number of figures: 3**

**Key words:** myelin oligodendrocyte glycoprotein, MOG, rituximab, neuromyelitis optica, optic neuritis.

## Abstract

**Objective:** To assess the effect of anti-CD20 B-cell depletion with rituximab (RTX) on relapse rates in myelin oligodendrocyte glycoprotein antibody-associated disorder (MOGAD).

**Methods:** Retrospective review of RTX-treated MOGAD patients from 29 centres in 13 countries. The primary outcome measure was change in relapse rate after starting rituximab (Poisson regression model).

**Results:** Data on 121 patients were analysed, including 30 (24.8%) children. Twenty/121 (16.5%) were treated after one attack, of whom 14/20 (70.0%) remained relapse-free after median (IQR) 11.2 (6.3-14.1) months. The remainder (101/121, 83.5%) were treated after two or more attacks, of whom 53/101 (52.5%) remained relapse-free after median 12.1 (6.3-24.9) months. In this 'relapsing group', relapse rate declined by 37% (95%CI=19-52%,  $p<0.001$ ) overall, 63% (95%CI=35-79%,  $p=0.001$ ) when RTX was used first line ( $n=47$ ), and 26% (95%CI=2-44%,  $p=0.038$ ) when used after other steroid-sparing immunotherapies ( $n=54$ ). Predicted 2-year relapse-free survival was 55% for first-line RTX therapy, and 18% for second-/third-line therapy. Circulating CD19<sup>+</sup> B-cells were suppressed to <1% of total circulating lymphocyte population at the time of 45/57 (78.9%) relapses.

**Conclusion:** RTX reduced relapse rates in MOGAD. However, many patients continued to relapse despite apparent B-cell depletion. Prospective controlled studies are needed to validate these results.

## Introduction

Autoantibodies targeting human myelin oligodendrocyte glycoprotein (MOG-IgG) have been identified in the sera of children and adults with a CNS inflammatory disease that is distinct from multiple sclerosis (MS).[1-3] 30-80% of patients relapse after an initial attack,[4-7] and some fulfil diagnostic criteria for aquaporin-4 antibody (AQP4-IgG)-negative neuromyelitis optica spectrum disorders (NMOSD).[7,8] A proportion of patients with MOG-IgG-associated disorder (MOGAD) accrue substantial disability and may benefit from long-term immunomodulatory treatment.[5-7,9,10] However, natural history and treatment responses in MOGAD are unclear.

Anti-CD20 B-cell depletion with rituximab (RTX) is effective in MS [11-14] and AQP4-IgG-NMOSD.[15-24] It is therefore hoped that RTX may be effective in MOGAD. However, its benefit is not yet defined, and several small case series suggest a lower efficacy than expected.[7,9,10]

## Objective

To examine the effectiveness of RTX in a large international cohort of MOGAD patients

## Methods

Investigators submitted anonymised retrospective data on all patients in their care meeting the inclusion criteria: (1) At least one clinical and MRI-confirmed CNS inflammatory event; (2) MOG-IgG positive by cell-based assay (live or fixed) incorporating full-length human MOG in its conformational form and an IgG-specific secondary antibody; (3) AQP4-IgG negative

by live or fixed cell-based assay; (4) treatment with RTX. Acceptable initial RTX dosing regimens were 1000mg on day 0 and day 15 or a body surface area [BSA]-adjusted dose of 375mg/m<sup>2</sup> weekly for 4 weeks. The interval between subsequent treatment courses was either fixed at 6-months or determined by periodic testing of circulating CD19<sup>+</sup> B-cell or CD19<sup>+</sup>/CD27<sup>+</sup> memory B-cell levels (maximum testing interval of 2 months). Both approaches have been used successfully in large cohorts of AQP4-IgG-NMOSD patients.<sup>15-24</sup>

Relapses were defined as a new or worsening symptomatic presentation, with a change in neurological examination, and confirmed by MRI as necessary.

Informed written consent and local ethics committee approval were mandatory for participation. All data were anonymised and were collected between August 2017 and September 2018.

### Statistical analysis

Stata version 15 and SAS version 9.3 were used for data analysis. A Poisson regression model was fitted to the data, with a random effect by patient level, to compare the relapse rate before and after initiating RTX. We compared median annualised relapse rates (ARR) pre- and post-RTX using Wilcoxon signed rank tests. ARR is defined as the total number of attacks divided by the number of years of disease. Relapse-free survival on RTX was estimated with Kaplan-Meier survival curves. Several subgroup analyses were performed.

### Results

Data were obtained from 29 centres in 13 countries – Argentina, Austria, Brazil, France, Germany, Netherlands, India, Italy, Japan, Korea, Switzerland, United Kingdom and United

States of America. The total number of MOGAD patients attending all study centres was 875. RTX was administered to 132/875 (15.1%). We did not have the resources to also obtain and analyse data on the 743 patients who were not treated with RTX. Eleven patients were excluded due to incomplete data (6), inadequate treatment protocol (4) and diagnostic uncertainty (1).

### *Demographics*

Data on 121 patients (71/121, 58.7% female) were analysed (table 1). Median (interquartile range, IQR) age at onset attack was 24.8 (13.1-39.6) years and age at first RTX infusion was 29.7 (18.2-44.0) years. Race distribution was 103/121 (85.1%) White, 10/121 (8.3%) Asian, 1/121 (0.8%) Black, and 7/121 (5.8%) mixed race. Paediatric patients (age <18 years at RTX initiation) comprised 30/121 (24.7%).

The most common MOGAD phenotypes in adults were relapsing optic neuritis (ON) (27/91, 29.7%) and relapsing ON with transverse myelitis (TM) (25/91, 27.5%). Acute disseminated encephalomyelitis (ADEM) with relapses (13/30, 43.3%) was the predominant paediatric phenotype.

### *Relapses and immunotherapy prior to rituximab*

For all patients, the median (IQR) disease duration prior to RTX initiation was 19.1 (5.9-55.0) months. RTX was started after the index attack in 20/121 (16.5%), and after at least two attacks in 101/121 (83.5%). The pre-treatment median (IQR) ARR was 1.82 (0.74-3.40) for the 101 relapsing patients, of whom 54/101 (53.5%) had received one or more prior non-steroid maintenance immunotherapies (table 1). These included azathioprine (26/101, 25.7%), mycophenolate mofetil (20/101, 19.8%), other immunosuppressive drugs (13/101,

12.8%), intravenous immunoglobulin (IVIg) (7/101, 6.9%), and MS disease-modifying therapies (MS-DMTs) (11/101, 10.9%, these are listed in the legend for table 1). There was no standardised ‘wash-out’ period of prior immunotherapies.

**Table 1:** Cohort demographics, clinical phenotypes and previous immunotherapies

	Whole cohort	Adults	Children	Single attack pre-RTX (all ages)	Multiple attacks pre-RTX (all ages)
Patients, n	121	91	30	20	101
Female, n (%)	71 (58.7)	56 (61.5)	15 (50.0)	14 (70.0)	57 (56.4)
White, n (%)	103 (85.1)	84 (69.4)	19 (63.3)	19 (95.0)	84 (83.2)
Median (IQR) onset age, yrs	24.8 (13.1-39.6)	33.0 (22.7-43.5)	7.6 (4.0-9.9)	31.9 (22.5-40.9)	23.2 (10.9-38.8)
Median (IQR) RTX start age, yrs	29.7 (18.2-44.0)	37.7 (25.5-48.5)	11.7 (8.3-14.0)	32.1 (22.7-41.5)	27.2 (16.4-44.1)
Disease onset <18years, n (%)	39 (32.2)	9 (9.9)	30 (100)	0	39 (38.6)
RTX initiation <18years, n (%)	30 (24.7)	0	30 (100)	0	30 (29.7)
Median (IQR) disease duration pre-RTX, mths	19.1 (5.9-55.0)	12.8 (5.0-49.1)	33.0 (16.3-69.6)	3.3 (1.7-5.1)	26.0 (9.8-70.9)
<b>Phenotypes, n (%):</b>					
Single attack	20 (16.5)	20 (21.9)	0	20 (100)	
- ON	6 (5.0)	6 (6.6)		6 (30.0)	
- TM	9 (7.4)	9 (9.9)		9 (45.0)	
- ON + TM	5 (4.1)	5 (5.5)		5 (25.0)	
Relapsing	101 (83.5)	71 (78.0)	30 (100)		101 (100)
- ON	29 (24.0)	27 (29.7)	2 (6.7)		29 (28.7)
- TM	6 (5.0)	5 (5.5)	1 (3.3)		6 (5.9)
- ON + TM	29 (24.0)	25 (27.5)	4 (13.3)		29 (28.7)
- ADEM/ADEM-like	15 (12.4)	2 (2.2)	13 (43.3)		15 (14.9)
- Other / brain involvement	22 (18.2)	12 (13.2)	10 (33.3)		22 (21.8)
Median pre-RTX ARR	2.25	2.34	1.64		1.82
No. of steroid-sparing ITs prior to RTX, n (%):					
- 0	66 (54.5)	59 (64.8)	7 (23.3)	19 (95.0)	47 (46.5)
- 1	35 (28.9)	19 (20.9)	16 (53.3)	1 (5.0)	34 (33.7)
- 2	13 (10.7)	9 (9.9)	4 (13.3)	0	13 (12.9)
- 3+	7 (5.8)	4 (4.4)	3 (10.0)	0	7 (6.9)
Types of prior steroid-sparing ITs prior to RTX, n (%)					
- None	66 (54.5)	59 (64.8)	7 (23.3)	19 (95.0)	47 (46.5)
- AZA	27 (22.3)	13 (14.3)	14 (46.7)	1 (5.0)	26 (25.7)
- MMF	20 (16.5)	14 (15.4)	6 (20.0)	0	20 (19.8)
- Other IS *	13 (10.7)	9 (9.9)	4 (13.3)	0	13 (12.9)
- IVIg	7 (5.8)	1 (1.1)	6 (20.0)	0	7 (6.9)
- Maintenance PLEX	2 (1.7)	1 (1.1)	1 (3.3)	0	2 (2.0)
- Any MS-DMT	11 (9.1)	8 (8.8)	3 (10.0)	0	11 (10.9)
- Injectable MS-DMT **	9 (7.4)	6 (6.6)	3 (10.0)	0	9 (8.9)
- Oral / infusible MS-DMT ***	5 (4.1)	5 (5.5)	0	0	5 (5.0)

\* Other IS comprised cyclophosphamide (6), mitoxantrone (3), methotrexate (2), tacrolimus (1) and ciclosporin (1). \*\* Injectable MS-DMT comprised beta-interferon (8) and glatiramer acetate (4). \*\*\* Oral / infusible MS-DMT comprised natalizumab (5), dimethyl fumarate (1), alemtuzumab (1) and fingolimod (1). Abbreviations: ARR, annualised relapse rate; ADEM, acute disseminated encephalomyelitis; AZA, azathioprine; IS, immunosuppressive drug; IT, immunotherapy; IQR interquartile range; IVIg, intravenous immunoglobulin; MMF, mycophenolate mofetil; MS-DMT, multiple sclerosis disease modifying therapy; ON, optic neuritis; PLEX, plasma exchange; RTX, rituximab; TM, transverse myelitis.

### *Rituximab dosing*

RTX was administered 6-monthly to 115/121 (95.0%). Others (6/121, 5.0%) were retreated according to repopulation of circulating CD19<sup>+</sup> B-cells or CD19<sup>+</sup>/CD27<sup>+</sup> memory B-cells. If only a single treatment course was given, treatment duration was considered as 6 months.

Most patients (79/121, 65.3%) received RTX 1000mg, administered either once (day 0), or twice (day 0 and day 15) per treatment course. A BSA-adjusted dose of 375mg/m<sup>2</sup> weekly for 4 weeks was given to 28/121 (23.1%) – predominantly paediatric patients. A minority of patients received a combination of both regimens (4/121, 3.3%), or exact dosing was not specified (10/121, 8.3%).

### *The effect of RTX started after index attack (n=20)*

RTX was started after the index attack in 20/121 (16.5%) cases from 11/29 centres. Because a proportion of MOGAD patients appear not to relapse irrespective of treatment (i.e. “monophasic disease”), we analysed this group separately from those with an established relapsing phenotype. After median (IQR) 11.2 (6.3-14.1) months on RTX, 14/20 (70%) remained relapse-free. Eleven relapses occurred in 6/20 (30.0%) patients, with a median (IQR) time to first relapse of 2.6 (1.3-4.5) months. The relapses comprised TM (6/11), ON (4/11) and simultaneous TM/ON (1/11).

*The effect of RTX started after two or more attacks (n=101)*

RTX was started after two or more attacks in 101/121 (83.5%). The median (IQR) pre-treatment duration was 26.0 (9.8-70.9) months. After median (IQR) 12.1 (6.3-24.9) months on RTX, 53/101 (52.5%) remained relapse-free. 102 relapses occurred in 48/101 (47.5%) patients (figure 2) with a median (IQR) time to first relapse of 4.4 (1.8-8.5) months. The relapses comprised ON (73/102, 71.6%), TM (17/102, 16.7%), ADEM/encephalitis (5/102, 4.9%), cerebellitis/rhombencephalitis (5/102, 4.9%) and multifocal/unspecified relapses (2/102, 2.0%). The Poisson regression model showed a 37% (95%CI 19-52%,  $p<0.001$ ) reduction in relapse rate following treatment with RTX. The Kaplan-Meier estimate of relapse-free survival was 55% (95%CI 44-65%) at 1 year of RTX therapy and 33% (95%CI 20-46%) at 2 years (figure 3a).

The effect of RTX on median ARR is shown in table 2. For all patients ( $n=101$ ), median AAR declined after initiation of RTX from 1.82 to 0.00 ( $p<0.001$ ; Wilcoxon signed rank test). Because calculation of ARR is dependent on pre- and post-treatment observation periods, we repeated the analysis after excluding patients with short observation periods (table 2). In patients with at least 12 months observation both pre- and post-RTX treatment (34/101, 33.7%), median ARR declined from 1.18 to 0.56 ( $p=0.002$ ; Wilcoxon signed rank test).

**Table 2:** The effect of rituximab on relapse rates in MOGAD

	Number of patients, n	Median (IQR) disease duration pre-RTX	Median (IQR) follow-up time on RTX	Reduction in relapse rate after RTX (95%CI), Poisson regression	Median (IQR) ARR pre-RTX	Median (IQR) ARR on RTX	Median change in ARR	Change in ARR, significance, Wilcoxon signed rank test
<b>Whole cohort (all patients with ≥2 attacks pre-RTX):</b>								
All patients	101	26.0 (9.8-70.9)	12.1 (6.3-24.9)	37% (19-52%) p<0.001	1.82 (0.74-3.40)	0.00 (0.00-1.25)	-1.09	p<0.001
Patients with ≥12mths observation pre-RTX	71	49.2 (23.1-99.0)	11.4 (6.0-21.9)		1.09 (0.64-1.90)	0.00 (0.00-1.26)	-0.46	p<0.001
Patients with ≥12mths observation post-RTX	51	25.2 (8.4-71.2)	24.9 (18.1-33.5)		1.84 (1.02-3.87)	0.43 (0.00-1.02)	-1.26	p<0.001
Patients with ≥12mths observation pre- and post-RTX	34	49.1 (27.5-80.0)	22.0 (16.7-29.9)		1.18 (0.73-1.68)	0.56 (0.00-1.17)	-0.40	p=0.002
<b>Exclusion of early relapses:</b>								
Exclusion of the first 1 month post-RTX	97	25.5 (9.4-70.0)	12.0 (6.4-25.1)	43% (26-57%) p<0.001	1.84 (0.84-3.47)	0.00 (0.00-1.25)	-1.09	p<0.001
Exclusion of the first 3 months post-RTX	88	25.7 (9.1-70.5)	13.7 (7.8-26.1)	55% (40-67%) p<0.001	1.83 (0.84-3.51)	0.00 (0.00-1.11)	-1.27	p<0.001
<b>Exclusion of patients co-treated with maintenance corticosteroid or steroid-sparing immunotherapies:</b>								
Patients on RTX monotherapy	61	29.3 (9.4-76.0)	11.3 (5.3-22.3)	42% (15-60%) p=0.005	1.54 (0.64-3.50)	0.00 (0.00-1.00)	-1.09	p<0.001
<b>Treatment naïve patients versus those with prior exposure to steroid-sparing immunotherapies:</b>								
Treatment naïve patients	47	14.8 (6.6-64.2)	10.0 (5.2-22.3)	63% (35-79%) p=0.001	2.36 (0.53-4.82)	0.0 (0.00-0.15)	-2.13	p<0.001
Prior immunotherapy exposure (any drug)	54	36.0 (18.8-72.3)	13.8 (8.0-26.8)	26% (2-44%) p=0.038	1.45 (1.01-2.51)	0.90 (0.00-1.79)	-0.61	p<0.001
Prior immunotherapy exposure (excluding MS-DMTs)	43	30.0 (18.0-71.2)	16.7 (8.0-27.5)	25% (-3-46%) p=0.077	1.23 (0.92-2.62)	0.62 (0.00-1.44)	-0.70	p<0.001
<b>Adults versus children:</b>								
Adults	71	26.0 (8.0-74.1)	12.7 (6.1-24.4)	42% (20-59%) p=0.001	1.84 (0.82-4.70)	0.00 (0.00-1.28)	-1.13	p<0.001
Children	30	33.0 (16.3-69.6)	11.8 (6.6-27.1)	29% (-7-53%) p=0.103	1.64 (0.76-2.92)	0.37 (0.00-1.12)	-0.75	p<0.001

Abbreviations: ARR, annualised relapse rate; 95%CI, 95% confidence interval; IQR, interquartile range; MS-DMT multiple sclerosis disease modifying therapy; RTX, rituximab.

### *Early relapses after starting RTX (n=97)*

Some studies of RTX in AQP4-IgG-NMOSD have described a lag time of 3-4 weeks to the onset of relapse-preventing action, despite complete B-cell depletion occurring within days of

RTX infusion.[20,25] We therefore re-analysed relapse rates after excluding relapses occurring within 1 month of RTX initiation (5/99, 5.1%). With this adjustment, the Poisson regression model showed a 43% (95%CI 26-57%,  $p<0.001$ ) reduction in relapse rate. Decline in median ARR was unchanged (table 2). If relapses occurring within 3 months of RTX initiation (26/99, 26.3%) are excluded, relapse rate reduced by 55% (95%CI 40-67%,  $p<0.001$ ) post-treatment.

#### *B-cell depletion (n=121)*

A CD19<sup>+</sup> B-cell count <1% of circulating lymphocytes is a commonly used indicator of effective B-cell depletion by RTX.[26] B-cell counts were available at the time of 57/113 (50.4%) relapses. In 12/57 (21.1%) relapses the CD19<sup>+</sup> B-cell count was  $\geq 1\%$ , indicating that the effect of RTX had waned. However, circulating CD19<sup>+</sup> B-cells were suppressed <1% in 45/57 (78.9%), indicating disease activity despite effective B-cell depletion. In 22/57 (38.6%) relapses, B-cells were completely undetectable.

#### *The effect of RTX on treatment naïve patients (n=47, 46.5%) versus those with prior exposure to non-steroid immunotherapies (n=54, 53.5%)*

A greater decline in median ARR ( $p=0.015$ , Mann Whitney U test) was observed in treatment naïve patients. Relapse rate declined by 63% (95%CI 35-79%,  $p=0.001$ , Poisson regression) in this group. After 1 and 2 years, 79% (95%CI 62-89%) and 55% of patients treated first-line with RTX are relapse-free respectively (Kaplan-Meier analysis, figure 3b).

When RTX was given second- or third-line, relapse rate declined by 26% (95%CI 2-44%,  $p=0.038$ , Poisson regression). After 1 and 2 years, 38% (95%CI 25-52%) and 18% (95% CI 7-34%) were relapse-free respectively (Kaplan-Meier analysis, figure 3b). Repeat analysis

after excluding the 11 patients with MS-DMTs exposure obtained similar results, though the 25% (95%CI -3-46%,  $p=0.077$ , Poisson regression) decline in relapse rate was not statistically significant. In the 11 patients exposed to MS-DMTs, median ARR declined from 2.19 pre-treatment (median observation period 49 months) to 1.79 after RTX initiation (median observation period 13 months). For the 7 patients with at least 12 months observation pre- and post-RTX, median ARR declined from 1.71 to 0.89.

#### *The effect of RTX in adults (n=71) versus children (n=30)*

All 30 children experienced two or more attacks prior to starting RTX. We therefore compared the effect of RTX in 30 children versus 71/91 (78.0%) adults, who had established relapsing disease pre-RTX (table 2). Median duration on RTX was 12.7 months for adults and 11.8 months for children, in which 31/71 (43.7%) adults and 17/30 (56.7%) children relapsed. Relapse rate declined by 42% (95%CI 20-59%,  $p=0.001$ , Poisson regression) in adults and by 29% (95%CI -7-53%,  $p=0.103$ ) in children. Treatment naïve patients comprised 40/71 (56.3%) adults versus 7/30 (23.3%) children. CD19<sup>+</sup> B-cell counts were available for 22/62 (35.5%) relapses in adults and 30/40 (75.0%) relapses in children, and were suppressed <1% in 19/22 (86.4%) and 21/30 (70.0%) respectively.

#### *Use of corticosteroids and steroid-sparing immunotherapies (n=121)*

Maintenance corticosteroid therapy, defined as daily or alternate day dosing of oral prednisolone, was used in 32/121 (26.4%) of patients while receiving RTX, of which 17/121 (14.0%) received continuous treatment, 7/121 (5.8%) were gradually tapered to cessation, and 8/121 (6.6%) restarted maintenance corticosteroids after relapse. Maintenance corticosteroid dosing did not follow a set protocol, so was individualised and variable throughout the observation period. It was therefore not possible to analyse corticosteroid use

in greater detail. Maintenance corticosteroids were not used in 78/121 (64.5%). Information about steroid use was not available in 11/121 (9.1%).

Continuation or addition of other immunotherapies with RTX occurred in 20/121 (16.5%) patients: mycophenolate mofetil (8), IVIg (6), azathioprine (3), methotrexate (2), IVIg with azathioprine (1). One patient received low dose IVIg (0.2mg/kg monthly) for RTX-induced hypogammaglobulinemia, which developed after 35 months of treatment. One patient had recent exposure to alemtuzumab (33 and 21 months pre-RTX).

Exclusion of all patients co-treated with maintenance corticosteroid and steroid-sparing immunotherapies left 61/101 (60.4%) patients (those who started maintenance corticosteroid only after a relapse were included in this analysis, but their follow-up was censored at the point of starting corticosteroid). For this group, the median (IQR) treatment duration was 11.3 (5.3-22.3) months. The Poisson regression model showed a 42% (95%CI 15-60%,  $p=0.005$ ) reduction in relapse rate following treatment with RTX. Median ARR declined from 1.54 to 0.00 ( $p<0.001$ ; Wilcoxon signed rank test).

#### *Treatment switches (n=121)*

22/121 (18.2%) patients discontinued RTX due to relapses (16/22, 72.7%), de-escalation of immunotherapy (5/22, 22.7%), and infection (1/22, 4.5%). They switched to mycophenolate mofetil (4), tocilizumab (3), azathioprine (3), IVIg (4) or multi-drug regimens.

#### *Expanded disability status scale (EDSS) scores (n=121)*

We compared EDSS at RTX initiation and at last review or on RTX discontinuation. EDSS data were available for 97/121 (80.2%) patients, but scores were not assessed at defined time

points with respect to relapses. Median (IQR) EDSS score improved from 3.0 (2.0-3.5) at RTX initiation to 2.0 (1.0-3.0) at follow-up ( $z=3.36$ ,  $p=0.001$ ; Wilcoxon signed rank test).

### *Tolerance and adverse events*

We did not systematically acquire data on adverse events. However, the following serious adverse events were reported: anaphylactoid infusion reaction (1), hypogammaglobulinemia (1) and cryptococcal meningoencephalitis (1). The latter occurred a 13-year-old boy on RTX for 2 years, with prior exposure to azathioprine and prednisolone. No patients died during treatment with RTX.

## **Discussion**

This is the first study examining the effectiveness of RTX in a large MOGAD cohort. RTX led to a 37% decline in relapse rate, and after 2 years, 33% of patients remained relapse-free. This is a less beneficial effect than observed with anti-CD20 B-cell depletion in MS and AQP4-IgG-NMOSD.[11-24] Where data were available, 79% of relapses occurred despite apparent robust B-cell depletion. The greatest treatment effect (63% decline in relapse rate) was observed in patients who received RTX as a first-line maintenance immunotherapy (see further discussion below). Patients receiving RTX second- or third-line experienced only a 25% decline in relapses. Separate analyses of adults and children suggested a better response in adult patients (42% versus 29% reduction in relapse rates).

The true benefit of RTX in MOGAD may be even less than that observed in this study, when one considers the potential influence of regression to the mean (the tendency of a group to return to the average, rather than to sustain an above average relapse rate). For example in randomised controlled MS trials, regression to the mean can account for up to 40% of the

1 reduction in relapse rate observed in both treatment and placebo arms.[27] In MOGAD  
2 cohorts, estimates of median ARR vary greatly and have been prejudiced by testing bias,  
3  
4 variable treatment paradigms and short observation periods. It is therefore difficult to  
5  
6 quantify the effect of regression to the mean in this study, but given that the observed  
7  
8 treatment effect is relatively small, it is particularly important to consider this phenomenon.  
9  
10

11  
12  
13 Previous studies of MOGAD treatment responses included smaller numbers of RTX-treated  
14  
15 patients. They also observed reduced relapse rates following RTX treatment. Some described  
16  
17 frequent early relapses: A German study reported that 6/9 patients relapsed on RTX  
18  
19 therapy.[7] An Australasian study included six RTX-treated patients, one of whom relapsed  
20  
21 twice despite B-cell depletion.[10] Finally, in a European paediatric study, 6/9 RTX-treated  
22  
23 children relapsed, including one life-threatening relapse despite confirmed B-cell depletion.  
24  
25 Of the three RTX responders, two were additionally receiving maintenance IVIg.[9]  
26  
27  
28  
29  
30  
31  
32  
33

34 It is not clear why RTX appears less effective for MOGAD than for MS and AQP4-IgG-  
35  
36 NMOSD. Phase I and II trials of RTX and phase III trials of ocrelizumab (another anti-CD20  
37  
38 therapy) in relapsing MS,[11-13] and retrospective studies of RTX in NMOSD,[15-24] have  
39  
40 consistently reported high efficacy. The largest meta-analysis of 46 NMOSD studies,  
41  
42 including 438 predominantly AQP4-IgG positive patients, calculated a 79% reduction in  
43  
44 relapse rate.[23] RTX has therefore become a dependable maintenance therapy for AQP4-  
45  
46 IgG-NMOSD in many countries.  
47  
48  
49  
50  
51  
52

53 One explanation for apparently poor efficacy is that this study has selected out a subgroup of  
54  
55 highly active treatment-refractory MOGAD patients from specialist centres. Only 15.1% of  
56  
57 all MOGAD patients at the participating centres were treated with RTX. The pre-treatment  
58  
59  
60  
61  
62  
63  
64  
65

1 median ARR (1.09 for those with >12 months of pre-treatment observation) was relatively  
2 high our study, as compared to unselected incident MOGAD cohorts.[5,6] A treatment  
3 paradox, in which higher relapse rates and poorer outcomes are seen in those receiving more  
4 therapy, reflects the *a priori* threshold for initiating such treatments and has been observed in  
5 other neuroinflammatory disorders.[28,29] In line with this, we observed a much better  
6 response in treatment-naïve patients versus those who had failed an alternative steroid-  
7 sparing maintenance therapy (63% reduction in relapses versus 25%). We also saw a  
8 paradoxical improvement in RTX effectiveness (42% reduction in relapses versus 37%) when  
9 excluding patients co-treated with maintenance corticosteroid and steroid-sparing  
10 immunotherapies.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

26 We explored if early relapses may account for poor treatment response, by excluding the 5%  
27 of relapses occurring within one month of RTX initiation. The decline in relapse rate  
28 increased slightly from 37% to 43%. The validity of this adjustment is uncertain in MOGAD,  
29 but stems from experience in AQP4-IgG-NMOSD, where a lag time of 3-4 weeks to achieve  
30 relapse-preventing effect has been described, despite complete B-cell depletion within days  
31 of RTX infusion.[20,25] Relapse risk may in fact be paradoxically high during this lag  
32 period,[30,31] but most consider this not to reflect truly RTX-refractory disease.[26] An even  
33 greater delay to therapeutic effect is possible: Decline in relapse rate improved to 55% when  
34 relapses within three months of RTX initiation were excluded. However, a more prolonged  
35 median follow-up than 12.1 months would be required to properly discriminate between  
36 delayed therapeutic onset and lack of efficacy.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55

56 Notwithstanding the above considerations, the obvious explanation may be that anti-CD20 B-  
57 cell depletion is indeed not as effective in MOGAD compared to MS and AQP4-IgG-  
58  
59  
60  
61  
62  
63  
64  
65

1 NMOSD. It is notable that most relapses occurred in the context of apparent robust B-cell  
2 depletion.  
3  
4  
5  
6

7 Despite their overlapping phenotypes, many differences have been identified between the  
8 immunopathogenic mechanisms underpinning these disorders. Both AQP4-IgG and MOG-  
9 IgG are immunoglobulin G1 antibodies, but the evidence that MOG-IgG is directly  
10 pathogenic to the CNS is less assured than for AQP4-IgG. It appears that the pathogenicity of  
11 human MOG-IgG is dependent on interactions with cognate T-cells.[32] Additionally, the  
12 abundance of circulating MOG-specific B-cells differs greatly between MOGAD patients,  
13 and does not correlate with serum titres of MOG-IgG.[33] It may therefore be that the  
14 predominant source of MOG-IgG production in some patients is by CD20<sup>+</sup> long-lived plasma  
15 cells in the bone marrow (which are not depleted effectively with RTX), rather than by  
16 continuous activation and differentiation of CD20<sup>+</sup> MOG-specific B-cells in the peripheral  
17 circulation. Systematic longitudinal assessment of MOG-IgG titres and B-cell populations  
18 were not available in this study but would be informative in future studies of RTX,  
19 particularly with respect to treatment failure.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

41 The children in this study experienced only a 29% (p=0.103) reduction in relapse rates on  
42 RTX, compared to the 42% decline observed in adults. Children comprised only a quarter of  
43 the cohort, and a much smaller proportion of children (23% versus 56% of adults) were  
44 treatment naïve prior to RTX. This may have confounded the comparison between adults and  
45 children, given that treatment-naïve patients appeared to respond more favourably to RTX.  
46 Finally, of all relapses known to have occurred in the context of inadequate B-cell depletion,  
47 9/12 (75%) occurred in children. This may suggest that children may benefit from closer B-  
48 cell monitoring. While possible, it seems unlikely that use of the BSA-adjusted dosing  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 regimen in children accounts for the lesser efficacy observed, as this is a conventional dosing  
2 protocol that is proven to cause complete circulating B-cell depletion with established  
3 efficacy in numerous autoimmune and haemato-oncological disorders.  
4  
5  
6  
7  
8

9 Although 45% of the cohort relapsed on RTX, only 18% switched to an alternative  
10 immunotherapy. This could be because relapses were mild or responded well to acute  
11 therapy. We could not explore this as EDSS data (which did show a trend towards improving  
12 disability) were available for only 80% of the cohort and were not calculated at designated  
13 time points with respect to relapses. Alternatively, neurologists may continue RTX despite  
14 ongoing MOGAD relapses due to limited third-line therapy options. Paediatric studies have  
15 suggested possibly superior responses to either IVIg or oral corticosteroid, but this requires  
16 further study.[9,34] Tocilizumab (interleukin-6 blockade) has been used effectively in some  
17 patients with RTX-refractory MOGAD.[35-37]  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33

34 Important limitations of this study include its retrospective design and the inclusion of many  
35 patients with relatively short duration of treatment. The latter will bias analysis of ARR, often  
36 utilised in this type of study, which is why we used Poisson regression to provide a more  
37 meaningful analysis of treatment effect. Other limitations include the absence of a relapse  
38 adjudication committee, and the heterogeneity of the cohort in terms of patient ages,  
39 MOGAD phenotypes and prior drug exposure. Furthermore, some patients received  
40 concomitant corticosteroid treatment at changing doses, there was no standardised washout  
41 from prior steroid-sparing medications and a minority of patients continued these treatments  
42 alongside RTX therapy. These limitations are inherent to real-world, retrospective studies of  
43 this nature and the inclusion of all cases improves the generalisability of the study and  
44 reflects the challenge of managing this rare and unpredictable disorder.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

In summary, this is largest study of RTX effectiveness in MOGAD. RTX seems less beneficial than expected for MOGAD, when compared with AQP4-IgG-NMOSD, supporting observations from small case series. Prospective studies in well-defined cohorts of adults and children are needed to confirm or refute our findings and to better understand the role of anti-CD20 therapy in the treatment of MOGAD.

## Figure Legends

**Figure 1:** Flow diagram demonstrating data analysis

**Figure 2:** MOGAD relapses occurring before and after treatment with rituximab

**Figure 3:** Kaplan-Meier plots of relapse-free survival following initiation of rituximab for (a) all relapsing patients (n=101); and (b) comparing treatment-naïve patients (blue line, n=47) and those with previous exposure to non-steroid immunotherapies (red line, n=54).

## References

1. O'Connor K, McLaughlin KA, De Jager PL, et al. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. *Nat Med* 2007;13(2):211-217.
2. Mader S, Gredler V, Schanda K, et al. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. *J Neuroinflammation* 2011;8:184.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
3. Kitley J, Woodhall M, Waters P, et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. *Neurology* 2012;79(12):1273-1277.
4. Lopez-Chiriboga AS, Majed M, Fryer J, et al. Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders. *JAMA Neurol* 2018;75(11):1355-1363.
5. Jurynczyk M, Messina S, Woodhall MR, et al. Clinical presentation and prognosis in MOG-antibody disease: A UK study. *Brain* 2017;140(12):3128-3138.
6. Cobo-Calvo A, Ruiz A, Maillart E, et al. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study. *Neurology* 2018;90(21):e1858-e1869.
7. Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. *J Neuroinflammation* 2016;13(1):280.
8. Hamid SHM, Whittam D, Mutch K, et al. What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients. *J Neurol* 2017;264(10):2088-2094.
9. Hachohen Y, Wong YY, Lechner C, et al. Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease. *JAMA Neurol* 2018;75(4):478-487.
10. Ramanathan S, Mohammad S, Tantsis E, et al. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. *J Neurol Neurosurg Psychiatry* 2018;89(2):127-137.

11. Bar-Or A, Calabresi PA, Arnold D, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. *Ann Neurol* 2008;63(3):395–400.
12. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing–remitting multiple sclerosis. *N Engl J Med* 2008;358(7):676–688.
13. Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. *N Engl J Med* 2017;376(3):221–234.
14. Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. *N Engl J Med* 2017;376(3):209–220.
15. Cree BA, Lamb S, Morgan K, et al. An open label study of the effects of rituximab in neuromyelitis optica. *Neurology* 2005;64(7):1270-1272.
16. Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. *Arch Neurol* 2008;65(11):1443-1448.
17. Pellkofer HL, Krumbholz M, Berthele A, et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. *Neurology* 2011;76:1310-1315.
18. Mealy MA, Wingerchuk DM, Palace J, et al. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. *JAMA Neurol* 2014;71:324-330.
19. Kim SH, Kim W, Li XF, et al. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B-cells in patients with relapsing neuromyelitis optica over 2 years. *Arch Neurol* 2011;68:1412-1419.
20. Kim SH, Huh SY, Lee SJ, et al. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. *JAMA Neurol* 2013;70:1110-1117.

- 1 21. Kim SH, Jeong IH, Hyun JW, et al. Treatment outcomes with rituximab in 100  
2 patients with neuromyelitis optica: Influence of FCGR3A polymorphisms on the  
3 therapeutic response to rituximab. *JAMA Neurol* 2015;72(9):989-995.  
4  
5  
6
- 7 22. Radaelli M, Moiola L, Sangalli F, et al. Neuromyelitis optica spectrum disorders:  
8 Long-term safety and efficacy of rituximab in Caucasian patients. *Mult Scler*  
9 2016;22(4):511-519.  
10  
11  
12
- 13 23. Damato V, Evoli A, Iorio R. Efficacy and safety of rituximab therapy in neuromyelitis  
14 optica spectrum disorders: A systematic review and meta-analysis. *JAMA Neurol*  
15 2016; 73(11):1342-1348.  
16  
17  
18
- 19 24. Cohen M, Romero G, Bas J, et al. Monitoring CD27+ memory B-cells in  
20 neuromyelitis optica spectrum disorders patients treated with rituximab: results from a  
21 bicentric study. *J Neurol Sci* 2017;373:335-338.  
22  
23  
24
- 25 25. Lindsey JW, Meulmester KM, Brod SA, et al. Variable results after rituximab in  
26 neuromyelitis optica. *J Neurol Sci* 2012;317(1-2):103–105.  
27  
28  
29
- 30 26. Kimbrough DJ, Fujihara K, Jacob A, et al. Treatment of neuromyelitis optica: review  
31 and recommendations. *Mult Scler Relat Disord* 2012;1(4):180-187.  
32  
33  
34
- 35 27. Martínez-Yélamos S, Martínez-Yélamos A, Martín Ozaeta G, Casado V, Camona O,  
36 Arbizu T. Regression to the mean in multiple sclerosis. *Mult Scler* 2006;16(6):826-  
37 829.  
38  
39  
40
- 41 28. Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for  
42 long-term outcome in patients with anti-NMDA receptor encephalitis. *Lancet Neurol*  
43 2013;12(2):157-165.  
44  
45  
46
- 47 29. Deiva K, Absoud M, Hemingway C, et al. UK Childhood Inflammatory  
48 Demyelination (UK-CID) Study and French Kidbiosep Study. Acute idiopathic  
49 transverse myelitis in children. *Neurology* 2015;84(4):341-349.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
30. Perumal JS, Kister I, Howard J, et al. Disease exacerbation after rituximab induction in neuromyelitis optica. *Neurol Neuroimmunol Neuroinflamm* 2015;2(1):e61.
31. Nakashima I, Takahashi T, Cree BA, et al. Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels. *J Clin Neurosci* 2011;18(7):997–998.
32. Spadaro M, Winklmeier S, Beltrán E, et al. Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein. *Ann Neurol* 2018;84(2):315-318.
33. Winklmeier S, Schlüter M, Spadaro M, et al. Identification of circulating MOG-specific B cells in patients with MOG antibodies. *Neurol Neuroimmunol Neuroinflamm* 2019;6:e625.
34. Wong YYM, Hacohen Y, Armangue T, et al. Paediatric acute disseminated encephalomyelitis followed by optic neuritis: disease course, treatment response and outcome. *Eur J Neurol* 2018;25(5):782-786.
35. Novi G, Gastaldi M, Franciotta D, et al. Tocilizumab in MOG-antibody spectrum disorder: a case report. *Mult Scler Relat Disord* 2019;27:312-314.
36. Hayward-Könnecke H, Reindl M, Martin R, Schippling S. Tocilizumab in severe recurrent anti-MOG-associated optic neuritis. *Neurology* 2019;92(16):765-767.
37. Ringelstein M, Kleiter I, Rommer P, et al. Long-term interleukin-6-receptor blockade in neuromyelitis optica spectrum disorder and MOG associated encephalomyelitis (P1344). Poster presented at: 35<sup>th</sup> Congress of the European Committee for Treatment and Research in Multiple Sclerosis; September 11-13, 2019; Stockholm, Sweden.